50 results
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
26 Apr 22
Departure of Directors or Certain Officers
6:51am
document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Danforth files a lawsuit for retaliation by Company
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
restated certificate of incorporation and third amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
30 Sep 19
EyeGate Enters Into Agreement for $1.9 Million Private Placement
6:55am
knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint
8-K
EX-10.1
pxr 6tpo8
6 Jan 21
EyeGate Enters Into Agreement for $8.0 Million Private Placement
6:55am
8-K
EX-10.1
wn9z1ki
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-10.1
ey2xocj54c
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-1.1
r6u33q45pgs
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-10.1
cpgs7v 1s3dlc2i0a0n
13 Apr 18
EyeGate Announces $11.25 Million Public Offering
12:00am
8-K
EX-10.1
sxck5nas10sua7v si3f
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
10-K
o1z8v 21lcrjbro81hwq
31 Mar 15
Annual report
12:00am
8-K
EX-1.1
nyssjr
26 Jul 22
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
4:31pm
8-K
EX-2.1
h43u1jpquic 15x
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am